Fluidigm turns to China's Puluoting to promote CyTOF

China’s Zhejiang Puluoting Health Technology Co., Ltd (PLTTECH) struck a licensing deal with US-based Fluidigm Corporation (NSDQ:FLDM). The two will advance the sales and application of the latter’s cytometry by time of flight (CyTOF) technology, as well as mass spectrometry flow panel and reagents in the clinical laboratory market in China, where clinical diagnostic filing for the CyTOF platform will be made. PLTTECH plans to acquire three CyTOF systems within 2 years to develop a blood cancer diagnosis panel (especially blood cancer in children) and immunotherapy prognosis panel. No financial details were disclosed.

Fluidigm acquired its CyTOF capabilities via the acquisition of DVS Sciences in 2014 to become a reference company in single cell technology. The firm's products can be used to provide clinical translational research support in the fields of cancer and immunotherapy, including identifying biomarkers. Fluidigm sells a variety of commonly used metal-antibody conjugates, and an antibody conjugation kit and has a global business presence.

PLTTECH is also focused on single cell precision research, utilizing world-class CyTOF technology and a biological information analysis platform to provide precision medicine and health management solutions through extensive collaboration in medical research, clinical diagnosis and treatment, drug development, and more.

Reference:
Biotech
Related news
Bayer pairs with CARD on hemophilia in China
German giant Bayer HealthCare entered into a memorandum of understanding with the China Alliance of Rare Diseases (CARD).
CARsgen Therapeutics files to hold HK IPO
Zhejiang Jolly Pharmaceutical Co., Ltd (300181.SZ) announced that CARsgen Therapeutics Holdings Ltd, in which its subsidiary Zhejiang Jolly Innovation Medical Investment Management Co., Ltd holds an 18.81% stake, has made an initial public offering (IPO) to the Hong Kong Stock Exchange.
HitGen partners with Uppthera on drug discovery
Chengdu-based HitGen Inc., (688222.SH), well-regarded in the global pharmaceutical community for its DNA encoded library (DEL) drug discovery platform, struck a partnership with South Korea-headquartered Uppthera Inc., to identify small-molecule targets against previously "undruggable" targets and novel E3 ligase.
Hangzhou's Apollomics files for HK IPO
Sino-US biopharma Apollomics Inc., which operates out of California (US) and Hangzhou (China), has filed to hold an initial public offering (IPO) to the Hong Kong Stock Exchange.
Hengrui greenlit for Phase II study SHR-1701/famitinib in SCLC
China-based Jiangsu Hengrui Medicine Co., Ltd (600276.SH) picked up a clinical trial approval in China to try out a combination therapy against small-cell lung cancer (SCLC).
Recent news
Brazil buys 20 million jabs of Bharat’s SARS-CoV-2 shot
Brazil’s Ministry of Health (MoH) last week signed a contract with local pharmaceutical company Precisa Medicamentos for the purchase of 20 million doses of Indian partner Bharat Biotech’s SARS-CoV-2 vaccine Covaxin, totalling BRL 1.6 billion (USD 288 million).
Bayer declines contraceptive contract in Argentina
Argentina’s Ministry of Health (MoH) last week launched two direct drug purchases aimed at procuring contraceptives from Bayer.
Mexico’s Genomma grows 9.1% during 2020
Mexico-based pharmaceutical firm Genomma Lab last week released 2020 financials, reporting MXN 13.9 billion (USD 670 million) turnover after 9.1% year-on-year (YOY) growth, and flaunting minor negative impact of the COVID-19 pandemic.
  • 1614588392046
  • Argentina,Brazil,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Ecuador ,Bolivia ,Mexico,Guatemala,Honduras,El Salvador,Belize,Nicaragua
  • Company
Argentina’s Richmond revealed as RDIF’s partner for local production of Sputnik V
Argentine pharmaceutical company Richmond last week signed a memorandum of understanding (MoU) with the Russian Direct Investment Fund (RDIF) for the local manufacturing of the latter’s SARS-CoV-2 vaccine Sputnik V, which was rolled out in the country in December last year.
FutureGen’s CLDN18.2 mAb wins tacit trial approval in China
China's Center for Drug Evaluation (CDE) website indicates that FutureGen Biopharma’s M108, a claudin 18.2 (CLDN18.2) targeted monoclonal antibody (mAb), has passed the clinical trial approval process and will be assessed in general advanced solid tumors.
Bayer pairs with CARD on hemophilia in China
German giant Bayer HealthCare entered into a memorandum of understanding with the China Alliance of Rare Diseases (CARD).
DaWei and Maccura partner on digital molecular diagnostics
Beijing-based DaWei Biotechnology, a microfluidic technology driven molecular diagnostics specialist, struck a partnership with leading domestic in vitro diagnostics company Maccura Biotechnology Co., Ltd (300463.SZ) on next-generation molecular diagnostics technologies.
Analytics Snapshot
Analytics Snapshot

GBI Logo
www.gbihealth.com
SH: +86 (21) 5302 2951
PRODUCTS
SUPPORT
Contact GBI
© 2021 GB Group Limited. All Rights Reserved.     Terms of Service Privacy Policy